Overview

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-05-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of BMS-986489 in Chinese participants with R/R SCLC (Relapsed/Refractory Small Cell Lung Cancer).
Phase:
PHASE1
Details
Lead Sponsor:
Bristol-Myers Squibb